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2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) and related compounds are a se-
ries of anti-cancer candidate pharmaceuticals (Table 1.), that have been shown to activate the 
AhR. We show that these compounds are high affinity ligands for the rat AhR, but a quantitative 
assay for their ability to induce CYP1A1 RNA in H4IIEC3 cells, a measure of activation of the 
AhR, showed a poor relationship between affinity for the AhR and ability to induce CYP1A1 
RNA. 5F 203, an agonist with low potency, was able to antagonise the induction of CYP1A1 
RNA by TCDD, while IH 445, a potent agonist, did not antagonise the induction of CYP1A1 
RNA by TCDD, and Schild analysis confirmed 5F 203 to be a potent antagonist of the induction 
of CYP1A1 RNA by TCDD in H4IIEC3 cells. In contrast, several benzothiazoles show potent 
induction of CYP1A1 RNA in human MCF-7 cells, and 5F 203 is unable to detectably antago-
nise the induction of CYP1A1 RNA in MCF-7 cells, showing a species difference in antago-
nism. Evaluation of the antiproliferative activity of benzothiazoles showed that the ability to 
agonise the AhR correlated with growth inhibition both in H4IIEC3 cells for a variety of ben-
zothiazoles, and between H4IIEC3 and MCF-7 cells for 5F 203, suggesting an important role 
of agonism of the AhR in the anti-proliferative activity of benzothiazoles.5/2/09 Page 2
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5F 203 (2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole) was originally synthesised 
(Hutchinson et al., 2001) as part of a programme to develop novel anti-cancer drugs; these 
agents have potent and selective activity against a variety of tumour cell lines. The specificity 
of the benzothiazole series against a range of cell types suggests a novel mode of action, and a 
pro-drug of 5F 203 is currently in clinical trials (Bradshaw et al., 2002).
Whilst investigating the mechanism of action of these drugs, it was shown that the induction of 
cytochrome P450 1A1 (CYP1A1) was a key response (Chua et al., 2000), and it has been pro-
posed that the induction of CYP1A1 causes metabolic activation of the benzothiazoles, thus 
causing genotoxicity (Leong et al., 2003) and thereby explaining their anti-cancer effect. The 
induction of CYP1A1 is known to be mediated by the Aryl Hydrocarbon Receptor (AhR) 
(Whitlock, 1999), a ligand-activated transcription factor. Several ligands of the AhR have been 
shown to have anti-cancer activity (Chen et al., 1998) (Abdelrahim et al., 2006) (McDougal et 
al., 1997), and interactions with the AhR may represent a mode of action for the benzothiazoles.
In agreement with this hypothesis, benzothiazoles cause nuclear translocation of the AhR, and 
transcriptional activation of this receptor (Loaiza-Perez et al., 2002). However,  there is no pub-
lished data as to whether anti-cancer benzothiazoles are ligands of the AhR. It has been reported 
that structurally related benzimidazole compounds can activate the AhR in the absence of lig-
and-binding (Dzeletovic et al., 1997) (Backlund et al., 1997) (Backlund and Ingelman-Sund-
berg, 2005), which appears to be a distinct mechanism of AhR activation. There is thus the 
possibility that benzothiazoles could activate the AhR by a non-ligand interaction with the AhR, 
and such a mechanism would have implications for understanding how these drugs act as anti-
cancer agents.
We have therefore undertaken to analyse the role of the AhR in the mechanism of action of these 
drugs by determining the ability of these compounds to bind ligand, quantifying the ability of 
these drugs to activate a specific target gene of the AhR, and relating these parameters to anti-
proliferative activity. The data show that benzothiazoles are ligands of the AhR, and quantita-
tive assessement of ligand-affinity and agonism reveals species-specific partial agonism of the 
AhR.5/2/09 Page 3
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Animals. Male Wistar rats CRL:WI (2-3 weeks, 200-250 g) were purchased from Charles River 
(UK). The animals were housed in cages under standard laboratory conditions (24°C, 60% hu-
midity, 12 hours dark/light cycle) and were given 3 days to adapt to standard laboratory condi-
tions. These animals were used for cytosol preparation following liver perfusion.
Cell culture. Both cell lines were purchased from Sigma ECACC and culture chemicals were 
purchased from Sigma. The H4-II-EC3 and MCF-7 cells were cultured in modified Eagle's me-
dium (MEM) containing sodium bicarbonate and supplemented with 10% foetal bovine serum, 
1% (200 mM L-glutamine, 10,000 U penicillin and 10 mg/ml Streptomycin) solution 100x, 1% 
MEM nonessential amino acid solution 100x. The cells were cultured in a humidified atmos-
phere with 5 % CO2 at 37°C.
Compounds and solutions. The radioligand [3H] - 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
(specific activity 29.8 Ci/mmol) was from ChemSyn Laboratories. The radioligand was diluted 
to the working concentration (200 nM) immediately prior to use. Unlabelled TCDD (purity 
99%) was from Cerilliant Cambridge isotope laboratories.  Tetrachloroazoxybenzene 
(TCAOB) was a gift from Dr. Andy Smith (MRC Toxicology Unit, Leicester). Benzothiazole 
test chemicals were synthesised in the Cancer Research Laboratories at the University of Not-
tingham, UK and the Drug Synthesis and Chemistry Branch, NCI, following published methods 
(Hutchinson et al., 2001). Thiazolyl Blue Tetrazolium Bromide, MTT chemical, (purity 98%), 
and Dextran-coated Charcoal (DCC) were purchased from Sigma.
[3H]-TCDD standard binding assay. The radioligand binding assay is slightly modified from 
the classic assay (Bradfield et al., 1988), except using TCAOB (Poland et al., 1976) as a com-
petitor. The frozen cytosolic aliquots from rat liver protein preparation were diluted in ice-cold 
MDENG buffer to a concentration of 5 mg of protein /ml prior to each experiment. 200 l aliq-
uots containing receptor preparation were incubated with a range of concentration of [3H]-
TCDD (0-2.6 nM). In order to define the non specific binding of [3H]- TCDD, the same exper-
iment was run in parallel with 1 l of unlabelled TCAOB (200-fold molar excess of [3H]-TCDD 
concentration) (added at least 15 minutes prior to [3H]-TCDD addition to allow equilibrium to 
be achieved) for 16 h at 4ºC. Each sample was analysed in triplicate. After the 16 h incubation, 
the assay was terminated by the addition of 30 l dextran-coated charcoal (2 g/mg protein) to 
remove unbound [3H]-TCDD. Samples were vortexed vigorously and incubated on ice for 10 5/2/09 Page 4
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was analysed by liquid scintillation counting.
Competitive binding assay. The competitive assays were run in triplicate essentially under the 
same conditions as for [3H]-TCDD standard binding assay. In order to determine the IC50 of the 
competitor that displaces [3H]-TCDD from specific sites, 200 l cytosolic preparations ± 
TCAOB (200 nM) ± varying concentration of unlabelled competitor (dissolved in DMSO) were 
incubated for at least 15 minutes to attain equilibrium prior to addition of 1 nM [3H]-TCDD. 
Samples were incubated for 16 h at 4ºC, and 30 l of each sample was analysed for total radio-
activity. After treatment with charcoal, the total and non-specifically bound [3H]-TCDD in the 
incubations was determined by liquid scintillation spectrometry.
Chemical treatment and CYP1A1 induction protocol. Benzothiazole test chemicals and cold 
TCDD were prepared in dimethyl sulfoxide (DMSO) at 20 mM and 10 M top stock solutions 
respectively. Prior to each experiment, concentrations were prepared in DMSO then further di-
luted with pre-conditioned medium into the working concentrations at the final concentration 
immediately before use. All experiments were conducted using the same source of each benzo-
thiazole test chemicals and one top stock solution of TCDD that was aliquoted in Eppendorf 
tubes and stored at -20°C for further use. For trials on TCDD and test chemicals with 10 M as 
the highest concentration, the final concentration of DMSO in the cultures was 0.1%, whereas, 
for trials on test chemicals with 30 M as the highest concentration, the final DMSO concen-
tration was 0.15%. At these concentrations, DMSO was not toxic and did not increase the 
CYP1A1 expression above the constitutive basal levels. The general conditions consist of seed-
ing H4-II-E cells and MCF-7 cells in triplicate wells at 1 x 105 cells and 5 x 104 cells per 180 
l, respectively, and incubated for 24 h at 37°C with 5% CO2. The following day, confluent cul-
tures (90-95% confluent) were treated with vehicle control (0.1 or 0.15)% DMSO as a negative 
control, TCDD (10 nM) as a positive control and the test inducer at the indicated concentrations 
for 4 h. Chemicals were diluted into 200 l of one day pre-conditioned medium (with the ex-
ception of the experiments in Figure 2, which used fresh medium), then 20 l of incubation me-
dium containing the chemical was added into the well for a total volume of 200 l. Untreated 
cells were included as a negative control in all experiments. To compare the maximal inducing 
effect for CYP1A1 mRNA for each chemical with that of TCDD, the concentration response 
curves for all test-chemicals were generated relative to the maximally inducing concentration 
of TCDD (10 nM), set arbitrarily at 100%. Following incubation with the indicated chemical(s), 5/2/09 Page 5
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cell pellets were washed and frozen at -20°C.
RNA and RT-PCR analysis. Total RNA from H4-II-E cells and MCF-7 cells was isolated, quan-
titated and 50 ng was reverse transcribed into cDNA and quantitative RT-PCR analysis per-
formed essentially as described (Bell et al., 2007), except that confluent cultures were lysed with 
0.2 ml of lysis buffer and the amount of cDNA used for multiplex PCRs was 2 ng. PCR effi-
ciencies were empirically determined for each probe, and varied from 109-118% for rat genes 
and from 110-125% for human genes.The cDNA sequences of the human CYP1A1, -actin and 
AhR are listed in Table 2. The three probes were analysed in the same real-time PCR reaction; 
CYP1A1 and AhR RNA levels are presented as a ratio to -actin, and -actin levels are present-
ed as a ratio to input cDNA.
MTT assay. The general procedure is essentially as described by (Bradshaw et al., 2002). MCF-
7 and H4-II-E cells were seeded in triplicate into 96-well microliter plates at a density of 2.5 x 
103 /180 l and 5 x 103 /180 l respectively and allowed 24 h to adhere before compounds were 
introduced (final concentration 0.1 nM to 10 mM, n = 8). Absorbance was read on Wallac 
Victor2 plate reader (Perkin Elmer) reader at 590 nm as a measure of cell viability.
Curve modelling and statistical analysis. All data are represented as mean ± SD. Statistical sig-
nificance is tested by Student's t-test or one-way analysis of variance (ANOVA) followed by 
Dunett’s Multiple Range Test. Groups were considered significantly different if p<0.05. KD and 
Bmax were determined from non-linear regression for single site binding hyperbola analysis by 
GraphPad Prism 5.0 Software (GraphPad Software Inc, San Diego, CA). [3H]-TCDD log con-
centration competition curves were fitted using non linear regression for single site competitive 
binding analysis, IC50 values represent the concentrations of test compound required to displace 
50% of [3H]-TCDD specifically bound to the Ah receptor. The concentration-response curves 
for the CYP1A1 mRNA induction were modelled using the variable slope sigmoid Hill equation 
(GraphPad Prism 5.0 Software). 5/2/09 Page 6
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Phenylbenzothiazoles are potent ligands for rat AhR
Saturation analysis of [3H]-TCDD binding to rat liver cytosol showed a typical saturation bind-
ing isotherm of [3H]-TCDD to rat liver cytosol (Fig 1A). The apparent KD for specific binding 
of [3H]-TCDD to rat liver cytosol and the concentration of binding sites, Bmax, were 0.37 ± 0.06 
nM and ~40 fmol/mg, respectively, over three repeats (Table 3.). The binding assay demon-
strates saturable and high-affinity specific binding of [3H]-TCDD to the Ah receptor, and thus 
the KD of [3H]-TCDD can be used to determine the binding affinities of the test compounds. In 
order to validate the competitive binding assay, unlabelled TCDD was used to displace [3H]-
TCDD from specific sites (Fig 1B), with an IC50 value of 1.65 nM (95% Confidence Interval, 
0.66 - 4.1 nM), and the calculated Ki for TCDD was 0.44 nM (95% CI, 0.18-11.1 nM). This is 
in agreement with the results of the saturation binding assay (KD 0.37 nM) which confirms that 
the conditions under which the displacement experiment is conducted are stable and yield re-
producible results as compared to the standard binding assay. 
To investigate the strength of the interactions between the test compounds and AhR, competi-
tive assays were conducted: Fig 1C shows the displacement of specifically-bound [3H]-TCDD 
by 5F 203. The Ki for 5F 203 was 2.8 nM (95% CI, 2-5 nM). Thus, 5F 203 is a high-affinity 
ligand for AhR. Further phenylbenzothiazole analogues were assessed for their ability to com-
pete with TCDD for binding to specific sites, and all the compounds in Table 1 yielded a Ki <10 
nM, showing that high affinity binding to the AhR is a common feature in this class of com-
pounds. 
CYP1A1 mRNA induction assay in H4-II-E cells: time course of effects
Given quantitative estimates of ligand-binding affinity, it was then important to develop a quan-
titative measure of AhR agonism in a TCDD-responsive rat cell line (Willett et al., 1998). The 
induction of CYP1A1 is well characterised as a measure of AhR agonism, and the time course 
of induction of CYP1A1 mRNA was measured, with a view to ensuring that the response was 
linear with time. The measurements of mRNA use normalisation against ß-actin mRNA, there-
fore, it was essential to test that ß-actin mRNA expression is not affected by treatment. An ad-
ditional reference gene used in this study was the AhR mRNA. Fig 2 B and D show ß-actin and 
AhR/ß-actin mRNA ratios relative to vehicle control at 4 h. The results show that both ß-actin 
mRNA and AhR/ß-actin mRNA ratios were within two-fold after all treatments at all time 5/2/09 Page 7
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with treatment or time. Thus, they are suitable to use as reference genes.
Fig 2 A reveals that TCDD significantly increased CYP1A1 mRNA levels after 4 h  of  treat-
ment, and maximal levels of induced CYP1A1 mRNA were achieved after 12 h of treatment. 
The induction of CYP1A1 mRNA by TCDD was shown to be linear over time up to 12 h. The 
time-course of the induction of CYP1A1 mRNA by 5F 203 was examined, since this compound 
may be metabolised. Fig 2C shows 5F 203 significantly increases CYP1A1/ß-actin mRNA ratio 
after 2 h treatment, before attaining maximal induction around 6-8 h. At 4 h of treatment with 
either TCDD or 5F 203, the induction of CYP1A1/ß-actin mRNA ratio was high enough to be 
measured reliably (>300-fold above control values) and was linear for both compounds. There-
fore, further experiments were conducted with 4 h exposure of cells to compound. 
Induction of CYP1A1 mRNA by TCDD and benzothiazoles in H4IIEC3 cells
In order to determine if these compounds were equally potent agonists, the concentration-re-
sponse curve for induction of CYP1A1 mRNA by TCDD and 5F 203 was determined. Meas-
urement of -actin and AhR RNAs confirmed that variation in these genes was less than two-
fold from control, confirming the reliability of the PCR measurement (Fig. 3B and 3D). The 
EC50 value for TCDD was 60 pM (95% CI, 33-100) (Fig 3A), and repeat assays gave a coeffi-
cient of variation for EC50 values of ~33%. However, the EC50 for 5F 203 was 3 M (95% CI, 
1.3-7.7 M) and the maximal levels of CYP1A1 mRNA induced by 5F 203 were not signifi-
cantly different from those obtained with TCDD. Thus, 5F 203 is a full agonist in this system, 
but is ~50,000-fold less potent than TCDD.
In order to determine if this was a unique characteristic of 5F 203, or typical of these com-
pounds, further phenylbenzothiazole analogues were tested for their ability to induce CYP1A1 
mRNA (Fig 3C). While IH 445 is a potent inducer for CYP1A1 with an EC50 of 4 nM (95% 
confidence interval 2-10 nM),  DF 203, GW 610 and AW 892 have EC50 values in the micro-
molar range; thus a low potency at inducing CYP1A1 RNA is a common feature to several ben-
zothiazoles. 
A quantitative comparison between binding to AhR (Ki) and CYP1A1 mRNA induction (EC50) 
is shown in Table 3. as the ratio. While IH 445 shows relatively good agreement between Ki and 
EC50, the other compounds are much less potent agonists than ligands, with 5F 203 having a 5/2/09 Page 8
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ifested by some phenylbenzothiazoles is a common property for several benzothiazoles, but that 
it is a compound-specific characteristic, since IH 445 is a relatively potent agonist.
Investigating the partial agonism of 5F 203 
The significant disparity between binding and induction measurements suggests two possibili-
ties: the first is a difference in intrinsic efficacy, and the second is a difference in metabolism or 
excretion of the compounds. The first possibility leads to the testable hypothesis that 5F 203 
would have an antagonistic effect on the ability of TCDD to induce CYP1A1. Fig 4 A shows 
the concentration-response curves of TCDD alone and in combination with 1 M 5F 203. 
TCDD had an EC50 value of 46 pM (95% CI, 13-160 pM) in the absence, and 5 nM (95% CI, 
2-12 nM) in the presence, of 1 M 5F 203; thus the EC50  for TCDD was shifted to the right by 
100-fold. Maximal levels of CYP1A1 RNA induced by TCDD in the presence and absence of 
5F 203 were not significantly different. IH 445 (Ki=0.9 nM) was used as a control; since it is a 
potent agonist for the induction of CYP1A1 mRNA in H4-II-E cells (Table 3.), it was predicted 
to have no antagonistic activity on induction of CYP1A1 RNA by TCDD. H4-II-E cells were 
co-treated with a range of concentrations of TCDD ± 3 nM IH 445 for 4 h, and Fig 4E shows 
the EC50 for CYP1A1 mRNA induction by TCDD was not significantly different in the pres-
ence (60pM (95% CI, 12-294)) or absence (30 pM (95% CI, 2-400)) of 3 nM IH 445, and thus 
there was no detectable antagonistic activity of IH 445. The related benzothiazole IH 445 fails 
to show detectable antagonism in this assay, and thus this demonstrates that the inhibition of 
induction of CYP1A1 RNA is not a non-specific consequence of the phenylbenzothiazole struc-
ture, but is chemical-specific. In summary, this experiment provides powerful evidence for ex-
cluding the possibility that poor availability of the 5F 203 could be the major reason behind the 
large quantitative difference in potency between 5F 203 and TCDD; if most of the 5F 203 were 
metabolised and/ or excreted, one would expect that there would be no change in potency of 
TCDD. 
Schild regression analysis
Fig 4 A shows that 5F 203 inhibited the induction of CYP1A1 mRNA by TCDD, but does not 
necessarily prove that this inhibition is competitive. To unravel the nature of this antagonism, 
Schild regression was performed. Fig. 4D shows that -actin and AhR RNA levels only show 
minor variation over the range of experimental conditions, and demonstrate the reliability of 5/2/09 Page 9
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mRNA by TCDD alone, and in combination with varying concentrations of 5F 203. The EC50 
of TCDD for CYP1A1 mRNA induction was measured at each concentration of 5F 203, and 
non-linear Schild regression analysis demonstrated a Schild slope of ~ 1 (95% CI, 0.5-1.8), and 
that the KB for 5F 203 was 23 nM (95% CI, 4-139). Thus antagonism by 5F 203 of the induction 
of CYP1A1 RNA by TCDD is not allosteric nor non-competitive but competitive. The KB is 
within 3-fold of the IC50 value determined by competitive binding assay fig 1C, and so the low 
potency of 5F 203 for inducing CYP1A1 mRNA in H4-II-E cells was shown to be a result of its 
antagonistic activity.
Induction assays in human MCF-7 cells
The ability of 5F 203 to act as an antagonist of TCDD at inducing CYP1A1 in human cells was 
investigated; MCF-7 cells were used since these showed inducibility of CYP1A1 by TCDD 
(Christou et al., 1994) and 5F 203 (Brantley et al., 2004). Fig.s 5B and D show that there was 
no significant difference in-actin or AhR RNAs under the range of experimental conditions 
tested. Fig 5A shows the concentration-response curves for TCDD and 5F 203 in MCF-7 cells. 
CYP1A1 mRNA was highly induced by 5F 203 and TCDD (~1600- and ~1700- fold above ve-
hicle control, respectively). The EC50 value for TCDD was 0.2 nM (95% CI, 0.07-0.6), and for 
5F 203 was 2 nM (95% CI, 0.9-5), only 10-fold less potent than TCDD. These results are in con-
trast to the marked difference in potency in rat cells.
The antagonistic activity of 5F 203 was investigated in MCF-7 cells by co-exposing cultures to 
increasing concentrations of TCDD ± 500 pM 5F 203 (Fig 5C). From fig 5C, the EC50 for 
TCDD in the absence of 500 pM 5F 203 was 300 pM (95% CI, 98-930] whereas in the presence 
of 500 pM 5F 203, the EC50 for TCDD was 400 pM (95% CI, 250-700), which was not signif-
icantly different. Thus 5F 203 had no detectable antagonistic activity on the induction of 
CYP1A1 RNA by TCDD in human MCF-7 cells.
Investigating the antiproliferative activity of benzothiazoles in MCF-7 and H4-II-E cells
Given the marked difference in ability of phenylbenzothiazoles to antagonise AhR between hu-
man MCF-7, and rat H4-II-E, cells, the antiproliferative activity of phenylbenzothiazole ana-
logues was characterised in these cell lines using the MTT cell viability assay (Table 4.). 
Camptothecin was used as a positive control, and gave potent growth inhibition in MCF-7 cells 
(19 nM, 95% CI 6-56 nM) (Fig 6B). 5F 203 and IH 445 decreased growth in MCF-7 cells with 5/2/09 Page 10
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sistent with previous reports (Hutchinson et al., 2001) (Bradshaw et al., 2002). TCDD treatment 
did not affect cell growth at any concentration tested and confirms that agonism of the AhR by 
TCDD per se has no inhibitory activity in MCF-7 cells.
H4-II-E cells were treated with these chemicals to investigate the antiproliferative activity of 
these compounds, using the same MTT assay (Table 4.). Fig 6 A shows that the positive control 
compound, camptothecin, had a GI50 of 67 nM (95% CI, 12-386 nM), and at concentrations ≥ 
100 nM was cytotoxic, whereas TCDD did not inhibit cell growth at any concentration tested. 
5F 203 failed to inhibit the growth of the cells up to 10 µM, the limit of solubility. In contrast, 
IH 445 was found to inhibit cell growth, with a GI50 value of 100 nM (95% CI, 40-248 nM). 
Thus the ability to agonise at the AhR correlated with anti-proliferative activity of benzothia-
zoles both across species (rat vs human cell lines) and within a species (5F 203 vs. IH 445).5/2/09 Page 11
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The ability of 5F 203 to displace specifically-bound TCDD from cytosol at nanoMolar concen-
trations characterises this phenylbenzothiazole as a high-affinity ligand of the AhR, and pro-
vides a basis for understanding the reported ability of this compound to activate the AhR 
(Trapani et al., 2003) (Loaiza-Perez et al., 2002). The high affinity of several of these chemicals 
in displacing specifically-bound cytosolic TCDD shows that this is a new series of ligands for 
the AhR that raise interesting questions about the structural requirements for binding to the 
AhR. SAR based upon the dioxin and furan series of ligands suggest a requirement for planarity 
and halogen atoms in the lateral position (Safe et al., 1986) (Poland and Knutson, 1982), but 
both of these shibboleths are questioned in the phenylbenzothiazole series, since 5F 203 is nei-
ther an obligate planar molecule (although it can assume a planar conformation), nor does it 
have exclusively lateral halogen atoms. The differences between the dioxin/ furan series, and 
phenylbenzothiazoles are not simply explained by conspicuously low affinity of the latter com-
pounds, since the affinity of 5F 203 and TCDD for AhR are within ten-fold. Thus this series of 
compounds provides evidence for the possibility that a much wider range of compounds may 
be high affinity ligands for AhR (Henry et al., 2006).
The affinity for binding to AhR has been shown to be predictive for the ability of dioxins and 
furans to activate AhR (Poland and Knutson, 1982), and so we envisaged testing if this relation-
ship held true for benzothiazoles. In order to make a quantitative evaluation of agonism, the RT-
PCR assay was designed to take samples at an early stage after dosing, thus minimising the ef-
fects of metabolism of compound, whilst showing a linear response to compound with time. Un-
der these circumstances, TCDD had an EC50 for inducing CYP1A1 RNA of 60 pM, comparable 
with previous studies (Sawyer and Safe, 1982). It was unexpected that the assay for induction 
of CYP1A1 RNA would yield such a large disparity between affinity and agonistic activity for 
5F 203. It is of interest that IH 445, which has a lateral alkyne group on the benzene ring (as 
opposed to the 3’ methyl group), is almost ~1000-fold more potent than the other benzothiazoles 
tested in this assay, suggesting a key role for the 3’ substituent in the agonism of AhR.
The low potency of 5F 203 in agonising the AhR may be explained through decreased bio-avail-
ability of the compound, partial agonism, or non-competitive activation of an alternative path-
way that inhibits the AhR signalling pathway. The ability of 5F 203 to inhibit the induction of 
CYP1A1 by TCDD provides compelling evidence that 5F 203 is available within the cell, and 
that decreased bioavailability of the compound is not the principal reason for its low potency. 5/2/09 Page 12
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quantitative measure of antagonism, and proves that the effect of 5F 203 is competitive with 
TCDD, and therefore is mediated through the AhR signalling pathway. Schild assay has previ-
ously been used to demonstrated that PCB 128 is a competitive antagonist of the fish AhR (Hes-
termann et al., 2000). It is apparent that several AhR ligands exhibit both agonistic and 
antagonistic activities (Zhou and Gasiewicz, 2003) (Palermo et al., 2003) (MacDonald et al., 
2004) (de Medina et al., 2005), and classical receptor theory predicts that partial agonists will 
cause different levels of response, dependent upon receptor number and receptor-coupling 
(Kenakin, 1997); indeed, cell-specific response to partial agonists of AhR has been demonstrat-
ed (Zhang et al., 2003). The relative quantification of these activities is essential for understand-
ing how AhR receptor number and coupling are related to the physiological and toxicological 
consequences of exposure to AhR ligands.
The induction of CYP1A1 RNA is a highly sensitive marker of AhR activation (Bell et al., 
2007), and measurement of CYP1A1 RNA provides a quantitative measure of AhR activation, 
that is arguably superior to measuring P450 protein activity, since effects such as regulation of 
translation, or inhibition of enzyme activity, can vitiate interpretation, and the effects of com-
pound metabolism can be minimised by measuring response at an early time point. This assay 
thereby enables a quantitative comparison between agonistic and antagonistic activities of AhR 
ligands. This represents an important advance, insofar as a great deal of existing literature de-
scribes antagonism of the AhR in a qualitative manner, and quantitative measurements will en-
able insight into the molecular mechanisms underlying ligand-specificity of response. So for 
example, where there is differential recruitment of cofactors by ligands of AhR (Boronat, 2007) 
(Hestermann and Brown, 2003) (Zhang et al., 2008), it would be of interest to quantitate the ag-
onistic and antagonistic activity of the ligands.
This report shows that 5F 203 exhibits principally antagonistic effects on the rat AhR, whilst no 
measurable antagonistic activity of 5F 203 can be detected in the human, MCF-7 cell line. 
Whilst this difference between rat and human cell lines could theoretically be ascribd to differ-
ences in receptor number or receptor coupling (Kenakin, 1997), direct measurements of AhR 
protein in these cell lines argues against a determinative role for receptor number (Holmes and 
Pollenz, 1997), and the similar EC50 for induction of CYP1A1 by TCDD between these two cell 
lines (Fig. 2, 5) argues that receptor-coupling is similar between the two cell lines. Species dif-
ferences in the AhR (Ema et al., 1994) itself is the most plausible explanation for the ability of 5/2/09 Page 13
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measurable antagonism in human cells. In agreement with the lack of antagonism of 5F 203 in 
human cells, 5F 203 is a potent agonist in MCF-7 cells, with an EC50 of 2.2 nM, 1000-fold more 
potent than in rat H4IIEC3 cells. Species-specific differences in partial agonism have been char-
acterised before between mouse and guinea-pig (Zhou et al., 2003), and this work shows that 
these are possible between human and other species, and extends the concept by showing quan-
titative differences between rat and human cells. Given the significant differences in the ligand-
binding affinity of AhR for TCDD that has been shown between mouse/rat and human as a re-
sult of the A381V residue (Ema et al., 1994) (Poland et al., 1994), it will be of interest to deter-
mine if this residue can also confer differences in partial agonism.
It has been proposed that the induction of CYP1A1 by 5F 203 is a key function of the anti-pro-
liferative activity of this compound (Trapani et al., 2003). Given that the partial antagonism of 
AhR by benzothiazoles will inhibit the induction of CYP1A1, we postulated that the antagonis-
tic activity of compounds would correlate with anti-proliferative activity both in rat cells, and 
when comparing rat and human cells. Thus the agonist IH 445 is relatively potent as a cytostatic 
agent in rat cells, while 5F 203 does not significantly decrease growth in the same rat cell line 
(Table 4.); 5F 203 also failed to exert cytostatic effects in rat kidney NRK/KNRK cells (RB, 
data not shown), confirming that the effect is not idiosyncratic to H4IIEC3 cells. When compar-
ing rat cells to human cells, the human cells were much more sensitive to 5F 203, compared to 
the rat cells, suggesting an important role for agonism of the AhR. However, TCDD by itself 
had no significant effect on the proliferation of either cell line, showing that agonism of the AhR 
by itself is insufficient to affect cell growth. These data suggest that it is a specific interaction 
of AhR-induced genes with 5F 203 that is responsible for the anti-proliferative activity of 5F 
203; one possibility is that cytochrome P450 is induced, and catalyses the formation of a reac-
tive and cytotoxic intermediate.
In summary, these data identify benzothiazoles as high affinity ligands for the AhR, and as spe-
cies-specific partial agonists for AhR. Current work is aimed at investigating the molecular na-
ture of the interaction between these ligands and the AhR, and characterising the nature of 
partial agonism with a variety of AhR ligands.5/2/09 Page 14
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Compound R1 R2 R3
5F 203 5F -Me -NH2
DF 203 H -Me, -NH2
GW 610 5F -OMe -OMe
AW 892 H -OMe -OMe
IH 445 5F -CCH -NH2
IH 318 5Br -Me -NH2
Table 1. Structures of 2-aryl-benzothiazoles.  The position and substituent of the phenylbenzothiazole ring 
is given by R1, and the R2  and R3 groups on the 2-phenyl ring is shown. The position of R1, 2 and 3 is shown on 
the figure.
Human Gene Oligonucleotide sequence Genebank accession No Labels
CYP1A1 
F
R
P
GTT GTG TCT TTG TAA ACC AGT G
CTC ACT TAA CAC CTT GTC GAT A
CAA CCA TGA CCA GAA GCT ATG GGT
NC_000015
FAM-BH1
AhR
F
R
P
ATA CAG AGT TGG ACC GTT TG
CTT TCA GTA GGG GAG GAT TT
TCA GCG TCA GTT ACC TGA GAG CCA
 NC_000007.12
HEX-BH2
ß-Actin
F
R
P
GAC ATG GAG AAA ATC TGG C
AGG TCT CAA ACA TGA TCT GG
ACA CCT TCT ACA ATG AGC TGC GTG T
NC_000007
ROX-BH1
Table 2. RT-PCR oligonucleotides primers for human genes. The primers and probes are identified by letters
designating the forward (F), and reverse (R) primer or the probe (P), and a number corresponding to the position of the base at
the 5’ end of the positive strand of primer or probe in the reference sequence, according to gene bank accession number.
Sequences are given from 5’→ 3’. The Reporter dye is at 5’ end of the oligonucleotide, and the quencher dye Black-Hole-1 or
-2 is at 3’ end. FAM, iscarboxy fluorescein; Hex, hexachlorofluorescein; ROX, 5(6)-carboxy-X-rhodamine5/2/09 Page 16
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Inducer
EC50 [nM] 
(95% confidence intervals)
Ki [nM] 
(95% confidence intervals)
Ki/EC50
TCDD 0.06 (33-100) 0.37 (0.18-1) 6.2
IH 445 4 (2-10) 0.9 (0.05-17) 0.2
5F 203 3000 (1300-7700) 2.8 (2-5) 0.00093
DF 203 3400 (900-13000) 9.9 (5-19) 0.003
GW 610 6500 (4000-12000) 6.8 (2-30) 0.001
AW 892 1900 (300-14000) 9.8 (4-22) 0.005
Table 3. Data for CYP1A1 mRNA induction and AhR binding in rat.  The concentrations that produce
half-maximal response EC50 were obtained from log concentration-response curves for CYP1A1 mRNA induction.
Inhibition dissociation constant (Ki) were obtained from the log concentration-TCDD competitive displacement curves.
The 95% confidence intervals are shown in brackets.
Compound
H4-IIE-C3
GI50 [nM] (95% 
confidence intervals)
MCF-7
GI50 [nM] (95% 
confidence intervals)
TCDD ND* ND*
Camptothecin 67 (12-386) 19 (6-56)
IH 445 100 (40-248) 14 (7-24)
5F 203 ND* 18 (8.7-39)
DF 203 ND* 1
GW 610 1400 (450-4300) 140 (51-370)
AW 892 223 (133-373) ND*
IH 318 >10000 NP
Table 4. Growth inhibitory potency of compounds in MCF-7 and H4-II-E cells.  To 
assess growth inhibitory activity of the compounds, cultures were plated for 24 h then treated 
with varying concentrations of each of the compouns listed. Cell viability was assessed by 
MTT assay after 3 days exposure. Curves were fitted using the sigmoidal response equation 
(GraphPad Prism 5.0 Software) and the concentration of compounds that inhibited the growth 
of cells by 50% (GI50) was estimated. The 95% confidence intervals are shown in brackets. (ND*) 
these compounds did not decrease the viability of the cells below the control levels (T0) signif-
icantly up to ~ 10 M. NP = not performed. 1 DF203 had a biphasic effect on growth inhibi-
tion. 5/2/09 Page 17
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FIG. 1. Binding affinity for the AhR. A, Saturation binding isotherm of [3H]-TCDD to rat 
liver cytosol, performed as described in materials and methods. The X-axis shows the concen-
tration of added [3H]-TCDD, and the Y-axis shows the concentration of specifically bound 
[3H]-TCDD. Data points represent the mean and Standard Deviation (SD) of triplicate determi-
nations. B, Competitive binding assay with TCDD. Rat liver cytosol was incubated with 1 nM 
[3H]-TCDD (open triangle), or with the indicated concentration of unlabelled TCDD (filled tri-
angle), with and without an excess of non-specific competitor, TCAOB. Specific binding is giv-
en as mean and SD of triplicate determinations. C, Competitive binding of 5F 203 to rat liver 
cytosol. As for B, but unlabelled 5F 203 was added to compete with the [3H]-TCDD. [3H]-
TCDD without added 5F 203 is shown as a triangle, with the indicated concentration of 5F 203 
by circles.
FIG. 2. Kinetics of induction of CYP1A1 RNA in H4IIEC3 cells. A, B. H4IIEC3 cells were 
treated with 0.5% (w/v) DMSO, or 10 nM TCDD in 0.5% DMSO, for the indicated period of 
time. RNA was isolated, and RT-PCR for CYP1A1 (A), -actin (filled symbols) and AhR (open 
symbols) RNAs (B) performed as described in Materials and Methods. -actin RNA levels were 
normalised against input cDNA, and AhR and CYP1A1 RNAs were normalised against -actin; 
all are presented as a % of vehicle control at four hours; all data points represent duplicate PCR 
determinations of quadruplicate biological replicates, and are shown as mean and SD. Samples 
that are significantly different from concurrent control (DMSO) at P<0.05 are indicated by an 
asterisk. C, D. As for A/B, but cells were treated with DMSO (squares), TCDD (circles) or 1 
M 5F 203 (triangles).
FIG. 3. Induction of CYP1A1 RNA by benzothiazoles. A, B. As for Figure 2, but cells were 
exposed to compound for 4 h in 0.1% (w/v) DMSO vehicle, and compound concentration is 
shown on the X-axis. CYP1A1/ -actin ratios are normalised to the maximal induced level at-
tained with TCDD, which is set as 100% response. Curves were fitted to the data using the var-
iable slope sigmoid Hill equation, as described in materials and methods. In A, TCDD is shown 
with a filled circle, whereas 5F 203 is shown with an open circle. B, -actin RNA is shown with 
filled symbols, whereas the AhR/ -actin ratio is shown with open symbols. Each point repre-
sents the mean and SD of triplicate samples. C, D. As for A/B, but using benzothiazole com-
pounds GW 610 (inverted triangle), AW 892 (square), DF 203 (diamond) and IH 445 (triangle). 
The TCDD data from A are shown in C/D for comparison, and dose-response curves were nor-5/2/09 Page 18
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periment. D, -actin RNA is shown with filled symbols, whereas the AhR/ -actin ratio is 
shown with open symbols.
FIG. 4. 5F 203, but not IH 445, antagonises the induction of CYP1A1 by TCDD in 
H4IIEC3 cells. A, B. H4IIEC3 cells were exposed for 4 h to TCDD alone (filled circles), 
TCDD and 1 M 5F 203 (open circles) or 1 M 5F 203 alone (open square). RNA was then 
isolated, and RT-PCR for CYP1A1/-actin ratio (A), or actin and AhR/-actin (B) per-
formed as described in Figure 3. C, D. As for A/B, but cells were exposed to TCDD alone (cir-
cle), TCDD plus 100 nM (diamonds), 300 nM (squares), or 1 M 5F 203 (inverted triangle), or 
5F 203 alone (triangle). Curves were fitted using a sigmoidal Hill slope, with a constant slope 
of 1. E, F. As for A/B, but H4IIEC3 cells were dosed with TCDD alone (filled circles), TCDD 
plus 3 nM IH 445 (open circles), or IH 445 alone (open squares).
FIG. 5. 5F 203 does not antagonise the induction of CYP1A1 RNA by TCDD in MCF-7 
cells. A, B. MCF-7 cells were treated with 0.1% DMSO (w/v), or the indicated concentration of 
TCDD (filled circle) or 5F 203 (open circles), and RNA isolated after 4 h treatment. RT-PCR 
was carried out as described in materials and methods, and A shows CYP1A1/ -actin ratio, 
whereas B shows -actin RNA, and the AhR/ -actin ratio. C, D. As for A/B, but cells were 
treated with TCDD alone (filled circles), TCDD plus 500 pM 5F 203 (open circles), or 5F 203 
alone (open square).
FIG. 6. Cytostatic effect of benzothiazoles in H4IIEC3 and MCF-7 cells. A, H4IIEC3 cells 
were seeded and incubated for one day, then treated with the indicated concentration of 5F 203 
(filled squares), Camptothecin (filled circles), TCDD (open circles), IH 445 (filled inverted tri-
angles), or 0.1 % DMSO (vehicle control), for three days. MTT assay was performed at the time 
of addition of drug (shown by T0, and a dotted horizontal line), and after three days incubation 
with drug, followed by measuring absorbance at 590 nm. Results are mean and SD of triplicate 
biological replicates. B, as for A, but in MCF-7 cells. 5/2/09 Page 19
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